Quantum Financial Statements From 2010 to 2024
| ALQGC Stock | EUR 0.07 0 1.77% |
Check Quantum Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Quantum Genomics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Quantum financial statements analysis is a perfect complement when working with Quantum Genomics Valuation or Volatility modules.
Quantum |
Quantum Genomics SA Company Shares Outstanding Analysis
Quantum Genomics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Quantum Genomics Shares Outstanding | 34.53 M |
Most of Quantum Genomics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Quantum Genomics SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Quantum Genomics SA has 34.53 M of shares currently outstending. This is 80.87% lower than that of the Biotechnology sector and 67.69% lower than that of the Health Care industry. The shares outstanding for all France stocks is 93.96% higher than that of the company.
Quantum Genomics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Quantum Genomics's current stock value. Our valuation model uses many indicators to compare Quantum Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Quantum Genomics competition to find correlations between indicators driving Quantum Genomics's intrinsic value. More Info.Quantum Genomics SA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Quantum Genomics' earnings, one of the primary drivers of an investment's value.About Quantum Genomics Financial Statements
Quantum Genomics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Quantum Genomics investors may analyze each financial statement separately, they are all interrelated. The changes in Quantum Genomics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Quantum Genomics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Quantum Genomics Socit Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It is also developing QGC011 that is in pre-clinical phase to treat hypertension with combination therapy and QGC006 to optimize the treatment of hypertension with a monotherapy drug. QUANTUM GENOMICS operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 13 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Quantum Stock Analysis
When running Quantum Genomics' price analysis, check to measure Quantum Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quantum Genomics is operating at the current time. Most of Quantum Genomics' value examination focuses on studying past and present price action to predict the probability of Quantum Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quantum Genomics' price. Additionally, you may evaluate how the addition of Quantum Genomics to your portfolios can decrease your overall portfolio volatility.